Will Insurance or a Government Scheme — Pay for Lenvatinib?

Generally, PMJAY covers inpatient hospitalization packages rather than outpatient medicines taken at home. Because lenvatinib is a daily oral tablet, its cost typically falls outside a standard PMJAY hospitalization package. Some state governments have added supplementary outpatient drug schemes beyond the base PMJAY entitlement; ask your oncologist's team whether your state has done this. Hospitalization packages for procedures related to your cancer treatment — scans, monitoring, managing side effects — may still apply and are worth claiming separately.

It depends entirely on your policy wording. Standard indemnity policies cover hospitalization and often exclude oral medicines taken at home. Critical illness and cancer-specific policies may pay a lump sum on diagnosis, which you can then use for drug costs. Look in your policy schedule for the phrases 'oral cancer therapy', 'targeted therapy' or 'outpatient cancer treatment', then call your insurer to ask directly. Do not assume cover exists — but do not assume it does not before you have read the wording and spoken to your insurer.

Yes. CDSCO has approved domestically manufactured generic versions of lenvatinib for the Indian market. Generics contain the same active molecule at the same dose and must meet CDSCO standards. The cost is substantially lower than the originator Lenvima brand. Ask your oncologist whether a CDSCO-approved generic is appropriate for your prescription and available at your treating centre or a nearby pharmacy. Many patients are not told about this option unless they ask, so it is worth raising directly.

Bring your CGHS card, a prescription from a CGHS-recognised oncologist that clearly states your diagnosis and the approved indication for which lenvatinib is being prescribed, and the relevant investigation reports supporting that indication. Present these at a CGHS empanelled pharmacy or wellness centre. If lenvatinib requires a special sanction rather than standard formulary dispensation, your treating doctor can initiate that application. Ask the wellness centre staff whether the drug is on the standard list before assuming a special sanction is needed — the process is different and faster if it is.

Start by asking your oncologist whether a CDSCO-approved generic lenvatinib is available — this is usually the most direct way to reduce the cost. Then ask your treating team whether the manufacturer has a patient assistance or compassionate access programme for your situation. Ask your centre's social worker or financial counsellor about state and NGO assistance programmes for cancer drug costs. Your oncologist has usually navigated this situation before and will know which options are realistic for your income level and state of residence.

Yes. For any scheme or insurer reimbursement, the prescription must state the cancer type and the approved indication for which lenvatinib is being used. CGHS and private insurers reimburse drugs for their approved indications; a claim for an off-label use is likely to be refused. CDSCO has approved lenvatinib for specific cancers, and your oncologist will prescribe it for the indication that applies to you. That indication must be clearly stated on any prescription or prior-authorisation form you submit with a claim.